Nektar Therapeutics has announced new data from the ongoing Phase 2b REZOLVE-AD clinical study evaluating rezpegaldesleukin, a first-in-class IL-2 pathway agonist and regulatory T-cell biologic, in patients with moderate-to-severe atopic dermatitis. The results were presented on November 8, 2025, in a late-breaking oral abstract session at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting. The study demonstrated statistically significant and clinically meaningful improvements in key efficacy endpoints, including mean ACQ-5 scores at week 16 versus placebo in patients with atopic dermatitis and a history of asthma. Additional improvements were observed across major endpoints such as EASI-75, EASI-90, vIGA-AD, and NRS-Itch at Week 16, with continued benefits noted from Week 16 to 24. Data from the long-term maintenance portion of the study, with 52 weeks of treatment, are expected in the first quarter of 2026. Nektar also indicated that top-line Phase 2b data for rezpegaldesleukin in alopecia areata will be reported in December 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-107821), on November 10, 2025, and is solely responsible for the information contained therein.
Comments